drugset / Trial / NCT05256108

Assessment of Abuse Potential of Cebranopadol in Humans

NCT05256108

Phase 1 Completed 38 enrolled Tris Pharma, Inc.
RandomizedCrossoverDouble-blindTreatment

Summary

This study will be conducted to evaluate the abuse potential of single doses of cebranopadol as compared with oxycodone, tramadol and matching placebo in recreational drug users.

Timeline

Start
2022-03-28
Primary completion
2022-07-12
Completion
2022-07-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Cebranopadol Small molecule 600 ug Oral
Subject Cebranopadol Small molecule 1000 ug Oral
Comparator Oxycodone Other / unclassified 40 mg Oral
Comparator Tramadol Other / unclassified 600 mg Oral

Indications